Evidence map›Paper›PMID 24237355›Full record

ArticleOmics : a journal of integrative biology2014

miR-429 identified by dynamic transcriptome analysis is a new candidate biomarker for colorectal cancer prognosis.

Yingnan Sun, Shourong Shen, Hailin Tang, Juanjuan Xiang, Ya Peng, Anliu Tang, Nan Li, Weiwei Zhou, Zeyou Wang, Decai Zhang and 5 more

Abstract read
In one paragraph

Article in Omics : a journal of integrative biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
  4. Review
  5. Targeting MALT1 Suppresses the Malignant Progression of Colorectal CancerFrontiers in cell and developmental biology · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. MiR-429 regulates gastric cancer cell invasiveness through ZEB proteins.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yingnan Sun1 Department of Gastroenterology, The Third Xiangya Hospital, Central South University , Changsha, Hunan, People's Republic of China .
Shourong Shen
Hailin Tang
Juanjuan Xiang
Ya Peng
Anliu Tang
Nan Li
Weiwei Zhou
Zeyou Wang
Decai Zhang
Bo Xiang
Jie Ge
Guiyuan Li
Minghua Wu
Xiayu Li

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a common malignant gastrointestinal cancer. Efforts for preventive and personalized medicine have intensified in the last decade with attention to novel forms of biomarkers. In the present study, microRNA and genetic analyses were performed in tandem for differential transcriptome profiling between primary tumors with or without nodes or distant metastases. Serial Test Cluster (STC) analysis demonstrated that 20 genes and two microRNAs showed distinctive expression patterns associated with the tumor, node, and metastasis (TNM) stage. The selected target genes were characterized by GO and Pathway analysis. A microRNA-target gene network analysis showed that miR-429 resided in the center of the network, indicating that miR-429 might serve important roles in the development of CRC. Real-time PCR and tissue microarrays showed that miR-429 had a dynamic expression pattern during the CRC progression stage, and was significantly downregulated in stage II and stage III clinical progression. The low expression of miR-429 was correlated with poor prognosis for CRC. Taken together, miR-429 warrant further clinical translation research as a candidate biomarker for CRC prognosis. Additional downstream targets and attendant gene function also need to be discerned to design a sound critical path to personalized medicine for persons susceptible to, or diagnosed with CRC.

Indexed as

Gene Expression Regulation, NeoplasticTranscriptomeBiomarkers, TumorCase-Control StudiesColorectal NeoplasmsDisease ProgressionFemaleGene Regulatory NetworksHumansLymphatic MetastasisMaleMicroRNAsMiddle AgedMolecular Sequence AnnotationMultigene FamilyNeoplasm StagingBiomarkers, TumorMicroRNAsMIRN429 microRNA, human

Identifiers

PMID24237355
PMCPMC3903170

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.